Browse by ▼

Johnson & Johnson

  • Watch This HCV Player

    By Brandy Betz - May 22, 2013 | Tickers: ABBV, GILD, JNJ

    Johnson & Johnson's (NYSE: JNJ) hepatitis C drug, simeprevir, recently received Priority Review status from the FDA. It was a surprising validation for Johnson's mid-stage project. But there are stronger candidates from Gilead (NASDAQ: GILD) and Abbvie (NYSE: ABBV) further ahead in the pipes.

    Simeprevir does have a trick up its sleeve. The drug could offer near perfect efficacy when used in combo therapies -- if the right company agrees more »

  • Is There Growth Left in Massive Drug Stocks?

    By Chris Hodge - May 22, 2013 | Tickers: JNJ, NVS, PFE

    In an already massive market segment, are dividends all you can hope for when you hunt down "elephants" like Warren Buffett does? While you probably won't get a five-bagger at this level, seeing a price increase in the 20%-50% range is very possible. In the case of stock splits, you may very well see adjusted share prices rise considerably. Plus, there's always the prospect of a company more »

  • More Danger Signs For The Market

    By Reuben Brewer - May 21, 2013 | Tickers: JNJ, MCD, PG

    The level of margin debt being used by investors is less than half a percentage point below the record set in July of 2007. The fact that the market is reaching new all time highs at the same time as margin debt is closing in on its previous record should be concerning.

    Big Numbers

    According to The Wall Street Journal, margin debt at the end of the first quarter was more »

  • 2013's Top 5 Companies for the Ordinary Investor

    By Kyle Colona - May 20, 2013 | Tickers: CVS, HD, JNJ, SBUX, WFM

    Since joining The Motley Fool blog network in January, my articles have linked public policy issues and current events to market sectors and companies in those sectors for ordinary investors to consider. This article takes a look at 5 of those suggestions across a number of market sectors based on first quarter performance and prospects for continued growth.

    The Health Care Sector

    Since the financial crisis of 2008 through the more »

  • Investing For The Other Half

    By Reuben Brewer - May 20, 2013 | Tickers: DRI, JNJ, MCD, DIS

    The severe market sell offs after the tech and housing bubbles appear to have left a large swath of the American public fearful of investing. That's not surprising, but it is a sad remnant of a difficult period. Dipping a toe back in the stock waters, however, can be done in a fun and relatively safe way by buying what you know.

    50%, or so

    The New York Time more »

  • Good News For Health Care Stocks Part 2

    By Reuben Brewer - May 17, 2013 | Tickers: JNJ, PRGO, TEVA

    It isn't surprising that providing Medicaid coverage to lower-income residents of Oregon led to an increased use of health care services. However, taking that finding a step further can lead to some interesting investing ideas.

    The Oregon Study

    The New England Journal of Medicine recently released the results of the Oregon Study. That research tracked Oregon's test of randomly assigning lower-income adults into a group that received Medicaid more »

  • Diagnosing Alzheimer's First

    By Seth Robey - May 17, 2013 | Tickers: BAX, LLY, JNJ, PFE

    Alzheimer's is a debilitating neurodegenerative disorder affecting approximately 5 million Americans, yet its causes are remarkably enigmatic.  Nonetheless, pharma and biotech companies continually throw money at potential blockbusters that lack innovative scientific forethought and inevitably fail to meet primary endpoints in clinical trials.  Their gamble is over a piece of the $203 billion pie that the Alzheimer's Association estimates as a 2013 cost of care (rising to an more »

  • A Quick Look at Avalon Advisor’s Big Buys Last Quarter

    By Aubrey Tabuga - May 17, 2013 | Tickers: ABBV, FITB, JNJ, TXN, DOW

    The 5 big buys of Avalon Advisors in the first quarter of 2013 are AbbVie (NYSE: ABBV), The Dow Chemical Company (NYSE: DOW), Texas Instruments (NASDAQ: TXN), Johnson & Johnson (NYSE: JNJ), and Fifth Third Bancorp (NASDAQ: FITB). Avalon Advisors is one of Houston’s largest money management firms. Based on whalewisdom.com compilation, the firm had over $1.646 billion in assets under management as of the end of the more »

  • Building An Income Fortress With Dividends Part II

    By Ken McGaha - May 16, 2013 | Tickers: JNJ, TWGP, WMT

    As promised at the end of Part I of this two-part article, in Part II, I am presenting three more selections that will help investors round out a well-diversified, income-producing portion of their investment portfolios that will provide them with a safe, growing stream of dependable dividends to supplement their overall investment strategy. In Part I, the three options presented provide exposure to the commercial real estate, technology, and private more »

  • Billionaire Bill Ackman: CEO's Clock Is Ticking

    By Marshall Hargrave - May 16, 2013 | Tickers: CL, JNJ, PG

    Billionaire Bill Ackman of Pershing Square Capital has been calling for the turnaround of the mega-cap consumer products company Procter & Gamble (NYSE: PG) for some time now. At the Sohn Investment Conference last week he reiterated his position on P&G, calling out the CEO Bob McDonald.

    Ackman's comments at the Sohn conference said he was willing to give CEO McDonald two to three quarters to get the company more »

  • What The DYI Investor Can Learn From The NFL Draft

    By Nicholas Ward - May 13, 2013 | Tickers: KO, CL, IBM, JNJ, ONVO, VIG, WFM, ZNGA

    With this article, I have set out to give investors a real-life example of portfolio strategy and asset allocation in relation to the National Football League's rookie draft. Often times, it is important for individuals to be able to step back and calm themselves when making high-pressure decisions (and aren't all investing decisions high-pressure?) by grounding their train of thought into something more tangible from the world around more »

  • My First Filter: Price to Book

    By John Hall - May 13, 2013 | Tickers: JNJ, PG, YHOO

    The Price to Book Ratio is my first (and favorite) filter when analyzing a consumer goods stock for purchase. 

    The Price to Book ratio is simply the stock's closing price divided by it's book value.  The result gives you a rough idea of how much you are paying for the assets the company owns.

    As an example, let's take a quick look at two large consumer goods more »

  • This High-Growth Health Care Stock's Troubles Continue

    By Robert Ciura - May 13, 2013 | Tickers: ISRG, JNJ, MAKO

    While the Dow Jones Industrial Average crosses 15,000 and the S&P 500 Index breaks historical records of its own, a high-growth health care stock languishes. Intuitive Surgical (NASDAQ: ISRG), known for delivering its investors spectacular revenue and earnings growth quarter-after-quarter, continues to struggle with swirling rumors and accusations regarding the safety of its revolutionary da Vinci surgical robots.

    Recently, CNBC reported that Intuitive Surgical warned hospitals that a more »

  • 5 Big Buys by Yacktman Asset Management in 1Q13

    By Aubrey Tabuga - May 13, 2013 | Tickers: CHRW, KO, JNJ, MSFT, SYY

    The five big buys of Yacktman Asset Management as of March 31, 2013, were Microsoft (NASDAQ: MSFT), Sysco (NYSE: SYY), Coca-Cola (NYSE: KO), Johnson & Johnson (NYSE: JNJ), and C.H. Robinson Worldwide (NASDAQ: CHRW). Headed by the investment guru, Donald Yacktman, the hedge fund has a total of $19.52 billion of assets under management based on data compiled by whalewisdom.com.

    I have briefly analyzed all of these from more »

  • 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part I

    By Meena Krishnamsetty - May 10, 2013 | Tickers: BMY, LLY, JNJ

    The healthcare sector has been known for paying dependable dividends and producing strong total returns over time. Among the major pharmaceutical companies, there are a few that stand out as most financially sound, as reflected by their CDS spreads below those of the U.S. Treasuries.

    Why use CDS spreads?

    A credit default swap is essentially like a form of insurance, that two parties can swap between one another for more »

  • London-Based Hedgie Focusing On Big Pharma

    By Meena Krishnamsetty - May 10, 2013 | Tickers: LLY, JNJ, MRK, MSFT, PFE

    By law, institutional investors with over $100 million in investment discretion in Section 13(f), are required within 45 days after the end of a calendar quarter to file the 13F form with the SEC. The 13F form discloses all of the US-listed publicly traded holdings in a fund's equity portfolio. One of the most recent filings belongs to London-based RWC Asset Management LLP. Reading on will take you more »

  • Should We Get Bullish on This Fast Growing Healthcare Company?

    By Anh HOANG - May 10, 2013 | Tickers: AGN, JNJ, NVS

    Allergan (NYSE: AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in the middle of April 2013. However, Allergan has experienced a lot of recent volatilty, and now is near $105. The company is in the portfolio of several successful investors including Joel Greenblatt and Jim Simons. Should investors consider Allergan at its more »

  • What to Buy and Sell as the Market Climbs

    By James Catlin - May 9, 2013 | Tickers: JNJ, KMB, KMI

    What happens when everyone seeks safety?

    We know the story: Fed intervention has spurned interest in low paying bonds, especially with the specter of inflation around the corner. Both savers and bond investors are being forced into an equity market in which they normally would not participate. Recently, CNBC reported that 25% of Central Banks will have committed or have plans to commit capital to the equity market.

    However, these more »

  • Is Buffett Bullish?

    By Nicholas Southwick - May 9, 2013 | Tickers: BRK-A, KO, JNJ, PG

    The answer, of course, depends on who is asking. The results are likely to be in the affirmative right now, but it would appear that Warren Buffett is letting go of some of Berkshire’s stock holdings, selling 19 million shares of Johnson & Johnson and almost a quarter of his Procter & Gamble (NYSE: PG) stake. The stocks have performed decently over the past year, but with Procter trading for 18 more »

  • 3 Blue Chips That May Be Cheaper Than They Seem

    By Joseph Harry - May 8, 2013 | Tickers: T, JNJ, MSFT

    When screening for investments, I often like to look at the forward price-to-earnings ratio as a metric that gives me an estimated glimpse into a company's future earnings power relative to its current price. If I find a disconnect -- when a company looks expensive when considering its trailing P/E ratio but fairly valued or even cheap when looking at its forward P/E -- I pay a little more more »

  • Page 1 of 24